KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Amortizatization of Intangibles (2017 - 2025)

Rigel Pharmaceuticals (RIGL) has 9 years of Amortizatization of Intangibles data on record, last reported at $243000.0 in Q4 2025.

  • For Q4 2025, Amortizatization of Intangibles fell 11.96% year-over-year to $243000.0; the TTM value through Dec 2025 reached $1.2 million, up 62.2%, while the annual FY2025 figure was $1.2 million, 62.2% up from the prior year.
  • Amortizatization of Intangibles reached $243000.0 in Q4 2025 per RIGL's latest filing, down from $467000.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $467000.0 in Q3 2025 and bottomed at -$116000.0 in Q4 2021.
  • Average Amortizatization of Intangibles over 5 years is $105700.0, with a median of $87000.0 recorded in 2023.
  • Peak YoY movement for Amortizatization of Intangibles: plummeted 690.0% in 2022, then skyrocketed 1266.67% in 2023.
  • A 5-year view of Amortizatization of Intangibles shows it stood at -$116000.0 in 2021, then skyrocketed by 254.31% to $179000.0 in 2022, then soared by 45.25% to $260000.0 in 2023, then grew by 6.15% to $276000.0 in 2024, then decreased by 11.96% to $243000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Amortizatization of Intangibles were $243000.0 in Q4 2025, $467000.0 in Q3 2025, and $250000.0 in Q2 2025.